Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
Primary Purpose
Constipation
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Polyethylene glycol 3350
Placebo, maltodextrin 500 powder for solution
Sponsored by
About this trial
This is an interventional treatment trial for Constipation focused on measuring Human Experimentation
Eligibility Criteria
Inclusion Criteria:
- Subjects (or parents/guardians of minors) must demonstrate their willingness to participate (or to have their children/wards participate) in the study and comply with its procedures by signing a written informed consent. Minor subjects must provide written assent.
- Subjects must be 17 years of age or older.
- Subjects must present with a current diagnosis of untreated constipation for 7 days or less based on having signs/symptoms of straining and hard or lumpy stools OR the inability to have a BM within 48 hours prior to randomization into the trial.
- Subjects must be OTC laxative users for the treatment of occasional constipation (defined as using a nonprescription laxative to treat at least 3 episodes of constipation within the last 12 months prior to randomization).
- Subjects must be willing to use study drug for up to 7 days as directed, and must agree to record bowel movement (frequency, consistency, etc.) accurately and consistently in a daily diary, and make two clinic visits.
- Subjects must be otherwise in good health, as determined by physical exam and medical history.
- Subjects must agree not to use any other products to treat their constipation during the course of the study.
- Subjects must agree not to use any medication known to cause constipation during the course of the study.
- Subjects must agree to maintain a similar diet from the week prior to randomization through end of study.
- Female subjects must be either surgically sterile, 2 years post-menopausal, or they attest that they are using an acceptable method of contraception (including hormonal birth control, IUD, double barrier methods, or vasectomized partner). In females of childbearing potential, the urine pregnancy test (HCG) must be negative at Baseline.
- Subjects must be able to read the diaries in English.
Exclusion Criteria:
- Subjects currently under a doctor's care and treatment for constipation.
- Subjects having current constipation episode for more than one week prior to randomization.
- Subjects that have a history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
- Subjects have a history of more than 3 months of constipation in the past year.
- Subjects have severe abdominal pain as the predominant constipation symptom.
- Subjects who have previously used a polyethylene glycol laxative.
- Subjects who have celiac disease or known gluten sensitivity.
- Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
- Subjects with known renal or hepatic insufficiency.
- Subjects with gastrointestinal bleeding or acute infection.
- Subjects with a history of alcohol or drug abuse.
- Subjects with a history of psychiatric disorders.
- Subjects with a history of significant ongoing medical problems, including kidney disease, or who are scheduled for surgical procedures.
- Subjects currently taking or taken within 7 days of randomization a concomitant medication that causes constipation including for example opiates, antidepressants, SSRI's, antimotility agents, and anticholinergics, etc.
- Subjects who plan to use laxatives during the treatment period other than the study medication.
- Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Subjects who have participated in an investigational clinical surgical, drug or device study within the past 30 days.
- Subjects who are pregnant or lactating.
- Subjects who are allergic to polyethylene glycol or maltodextrin.
- Subjects who are employed or have immediate family members employed by a company that manufactures laxative products.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Polyethylene glycol 3350 powder for solution
Placebo
Arm Description
MiraLAX® (polyethylene glycol 3350 powder for solution)
MALTRIN 500® M500 (maltodextrin 500)
Outcomes
Primary Outcome Measures
Number of Participants With a Complete Resolution at the Final Visit
A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00770432
Brief Title
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
Official Title
A Randomized, Placebo-Controlled, Double-Blind, Trial of Polyethylene Glycol 3350 Laxative for the Treatment of Occasional Constipation.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
Human Experimentation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
203 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Polyethylene glycol 3350 powder for solution
Arm Type
Active Comparator
Arm Description
MiraLAX® (polyethylene glycol 3350 powder for solution)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
MALTRIN 500® M500 (maltodextrin 500)
Intervention Type
Drug
Intervention Name(s)
Polyethylene glycol 3350
Other Intervention Name(s)
MiraLAX®
Intervention Description
Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
Intervention Type
Other
Intervention Name(s)
Placebo, maltodextrin 500 powder for solution
Other Intervention Name(s)
MALTRIN® 500 powder for solution
Intervention Description
Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
Primary Outcome Measure Information:
Title
Number of Participants With a Complete Resolution at the Final Visit
Description
A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.
Time Frame
24 hours to 3 days after last dose of seven day treatment period.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects (or parents/guardians of minors) must demonstrate their willingness to participate (or to have their children/wards participate) in the study and comply with its procedures by signing a written informed consent. Minor subjects must provide written assent.
Subjects must be 17 years of age or older.
Subjects must present with a current diagnosis of untreated constipation for 7 days or less based on having signs/symptoms of straining and hard or lumpy stools OR the inability to have a BM within 48 hours prior to randomization into the trial.
Subjects must be OTC laxative users for the treatment of occasional constipation (defined as using a nonprescription laxative to treat at least 3 episodes of constipation within the last 12 months prior to randomization).
Subjects must be willing to use study drug for up to 7 days as directed, and must agree to record bowel movement (frequency, consistency, etc.) accurately and consistently in a daily diary, and make two clinic visits.
Subjects must be otherwise in good health, as determined by physical exam and medical history.
Subjects must agree not to use any other products to treat their constipation during the course of the study.
Subjects must agree not to use any medication known to cause constipation during the course of the study.
Subjects must agree to maintain a similar diet from the week prior to randomization through end of study.
Female subjects must be either surgically sterile, 2 years post-menopausal, or they attest that they are using an acceptable method of contraception (including hormonal birth control, IUD, double barrier methods, or vasectomized partner). In females of childbearing potential, the urine pregnancy test (HCG) must be negative at Baseline.
Subjects must be able to read the diaries in English.
Exclusion Criteria:
Subjects currently under a doctor's care and treatment for constipation.
Subjects having current constipation episode for more than one week prior to randomization.
Subjects that have a history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
Subjects have a history of more than 3 months of constipation in the past year.
Subjects have severe abdominal pain as the predominant constipation symptom.
Subjects who have previously used a polyethylene glycol laxative.
Subjects who have celiac disease or known gluten sensitivity.
Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
Subjects with known renal or hepatic insufficiency.
Subjects with gastrointestinal bleeding or acute infection.
Subjects with a history of alcohol or drug abuse.
Subjects with a history of psychiatric disorders.
Subjects with a history of significant ongoing medical problems, including kidney disease, or who are scheduled for surgical procedures.
Subjects currently taking or taken within 7 days of randomization a concomitant medication that causes constipation including for example opiates, antidepressants, SSRI's, antimotility agents, and anticholinergics, etc.
Subjects who plan to use laxatives during the treatment period other than the study medication.
Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
Subjects who have participated in an investigational clinical surgical, drug or device study within the past 30 days.
Subjects who are pregnant or lactating.
Subjects who are allergic to polyethylene glycol or maltodextrin.
Subjects who are employed or have immediate family members employed by a company that manufactures laxative products.
12. IPD Sharing Statement
Citations:
PubMed Identifier
27158544
Citation
McGraw T. Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial. World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):274-82. doi: 10.4292/wjgpt.v7.i2.274.
Results Reference
derived
Learn more about this trial
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
We'll reach out to this number within 24 hrs